View as an RSS Feed
View Natty Greene's Articles BY TICKER:
Why Imminent Orphan Status Designation Will Attract Big Pharma To Mast Therapeutics
- Likely positive orphan status opinion for MST-188 (for ALI) in EU next week provides imminent catalyst.
- Big pharma are actively acquiring and partnering with small biotechs treating sickle cell disease like MSTX.
- This week's setback by sickle cell disease competitor (GLYC) creates advantage for MSTX.
- Recent analyst opinion points to upside of 100%+ based on MSTX price target of $1.20.
Imminent District Court Ruling Should Propel Zogenix Higher
- Zogenix (ZGNX) stock has experienced severe weakness over the last three months dropping 65%.
- Effort by Massachusetts Governor to ban recently launched drug, Zohydro, has created uncertainty.
- Imminent ruling by District Court Judge Zobel will determine near term direction of stock.
- Expected preliminary injunction ruling on forced failure requirement will provide bullish catalyst.
Pitt Hyde & Mason Hawkins Buy >50% Stake In GTx Ahead Of Phase II Results
- GTXI has recently seen extraordinary insider buying and outside investment of $38 million.
- Investors Pitt Hyde and Mason Hawkins have a successful track record of identifying undervalued companies poised for growth.
- New investments in GTXI coincide with imminent catalyst of the release of Phase II trial results for metastatic cancer drug, Enobosarm.
- Based on recent, positive Phase II trial results for other cancer drugs in sector, the average near-term gain is 109% post results release.
- Groupon's Achilles' Heel: Blue Calypso's Patents
- Why Pfizer And Publix Will Ramp Up Acura Pharmaceuticals
- Is Yelp's Mobile Growth At Risk?
- Expecting Positive Phase III Results For GTx's Cancer Muscle-Wasting Drug
- Institutions Increase Ownership In Venaxis
- Glu Mobile Games Rise In China's Top Grossing Rankings
- Judge Ruling A Big Win For MGT Capital
- 2 Near-Term Catalysts To Propel InVivo Shares Higher
- MGT Capital Picked To Win First Round Litigation Against Casino Heavyweights
- Key Meetings Likely To Bring WMS And MGT Closer To Settlement
- Near-Term Catalyst Provides Attractive Opportunity For MGT Capital Investors
- FDA Upgrades Acura Pharmaceuticals To A Public Health Priority
- An Alternative Reading Of FDA Briefing Materials On Titan's Probuphine
- Titan Presents Compelling Opportunity Ahead Of PDAC Vote
- Titan As A Hedge For Zogenix
- InVivo Therapeutics: Why Run-Up To March 9 Likely
- Why Venture Capital And Insiders Are Buying Glu Mobile
- Bullish Catalysts Make GTx Top Biotech Buy For Q1 2013
- Majesco Partners With Inc. Magazine's Company Of The Year
- Positive Year End Catalysts Make Acura A Buy
- Glu Mobile: Beating Zynga And Electronic Arts To Mobile Growth
- Glu Mobile Outperforms Zynga In 3 Key Growth Metrics
- Kit Digital Is An Attractive Acquisition Target For IBM Or Private Equity
- Investors Are Not Too Late To Gain From Glu Mobile's Likely Valuation Of Up To $10/Share
- Analyzing GTx, Inc.'s Vast Upside Potential
- Pfizer's $150M Bet On Acura Pharmaceuticals Is Good News For Investors
- Zogenix: Smart Biotech Buy Before Earnings
- Insiders And Institutions Aggressively Buying Zogenix
- Zynga's Talent And IP Acquisition Strategy Post IPO